Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences

Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.

University Of Pittsburgh Medical Center Makes $1 Million In-Kind Investment In Zellerx Corporation To Develop Natural-Killer Cell Therapy For Cancer​

PITTSBURGH, February 7, 2005 — The University of Pittsburgh Medical Center (UPMC) today announced that it will provide services valued at more than $1 million to ZelleRx Corp., a biopharmaceutical company developing cancer treatment candidates based on its proprietary natural-killer (NK) cell line, in exchange for equity in the company.

The services provided will include support of Phase I and Phase II clinical trials for ZRx101, ZelleRx’s novel cancer treatment. ZRx101 was developed using the company’s proprietary natural-killer cell line, NK-92. The trials will focus first on melanoma, however, later trials may include other cancers.

To date, 25 patients have been treated with ZRx101 for renal and melanoma cancers in Chicago, and advanced cancers in young adults (leukemia and sarcomas) in Frankfurt, Germany. The company recently announced clinical data from the first 12 patients of the U.S. trial at Rush University Medical Center in Chicago, and has assumed the Investigational New Drug application with the FDA previously held by the inventor Hans Klingemann, M.D.

“The University of Pittsburgh Cancer Institute is the ideal clinical development partner for ZRx101 because it is home to the world’s leading experts on natural killer cells, and both the research and clinical teams are highly experienced in the use of biologic therapies for cancer,” said Gary Keller, president and CEO of ZelleRx.

NK cells are the first cells of the body's immune defense system that seek to search out and destroy cancer tumors and other infected cells. The use of NK cells for cancer therapy has emerged as a leading novel approach to treating cancer since biologic therapies can have fewer side effects than traditional chemotherapy.

NK cells were originally identified in the early 1970s at the National Institutes of Health (NIH) in the laboratory of Ronald B. Herberman, M.D., who, after leaving the NIH in 1985, joined the University of Pittsburgh Cancer Institute as its founding director.

“It is exciting for the University of Pittsburgh Cancer Institute to play a leading role in exploring the therapeutic effects of this very potent, standardized NK cell therapy, which I believe has great potential to benefit patients with various types of cancer,” said Dr. Herberman.

About UPCI
UPCI is one of the nation’s select National Cancer Institute-designated Comprehensive Cancer Centers and the only one in western Pennsylvania. UPCI investigators are world-renowned for their work in clinical and basic cancer research. For more information on cancer research at UPCI, please visit the Web site at

About UPMC
The University of Pittsburgh Medical Center is the leading integrated delivery system for health care in Pennsylvania. UPMC is dedicated to providing exemplary patient care, educating the next generation of health care professionals and advancing biomedical research. UPMC includes primary care and specialist physician practices, rehabilitation services, in-home services, retirement living options, a mail-order pharmacy, occupational medicine services, durable medical devices, technology transfer ventures and international health care initiatives. For more information visit

About ZelleRx
ZelleRx Corporation is a biopharmaceutical company developing cancer treatment products based on its proprietary natural killer (NK) cell line, NK-92. The company has a pipeline of universal and targeted products in clinical development against a variety of cancers as adjuvant and primary therapies. For more information visit

UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by Healthwise, Incorporated. To learn more, visit

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

Pittsburgh, PA, USA |